Citation Tools
PDFLate-breaking abstracts
Clinical trials in-progress
812 Urelumab (anti-CD137 agonist) in combination with vaccine and nivolumab treatments is safe and associated with pathologic response as neoadjuvant and adjuvant therapy for resectable pancreatic cancer
Download to a citation manager
Download the citation for this article by clicking on one of the following citation managers:
- Cite this article as:
- 812 Urelumab (anti-CD137 agonist) in combination with vaccine and nivolumab treatments is safe and associated with pathologic response as neoadjuvant and adjuvant therapy for resectable pancreatic cancer